Chembio Starts Distribution of Third-Party COVID-19 Antigen Assay

by Vandana Singh, Benzinga Editor

August 27, 2021 8:34 AM | 1 min read |

Chembio Diagnostics Inc CEMI has launched the commercial distribution of an FDA-Emergency Use Authorized rapid point-of-care COVID-19 antigen test.
Product inventory is on-hand and immediately available for shipment to Chembio customers across the U.S.
The SCoV-2 Ag Detect Rapid Test, manufactured by InBios International Inc, is a rapid immunoassay test.
It provides results in 20 minutes from a nasal swab and requires no instrumentation.
The test can be used for both patients who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset and for asymptomatic serial testing.
Related Content: Chembio Q2 Earnings Lag Consensus.
Price Action: CEMI shares are up 16.4 at $3.13 during the premarket session on the last check Friday.

Posted In: News Penny Stocks Health Care Contracts Movers Trading Ideas General Briefs COVID-19 Coronavirus Diagnostics

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.